Utrogestan Versus Nifedipine as Tocolysis for Preterm Labor: a Randomised Controlled Trial

• Status: Unknown status
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

RESEARCH HYPOTHESIS

-Incidence of preterm delivery is lower in women treated with oral micronized progesterone (Utrogestan) as acute tocolysis agent compare to Nifedipine group with fewer maternal side effect

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: nor zila hassan malek
• Treatments: Nifedipine; Progesterone

Criteria

Inclusion Criteria:

• Singleton pregnancy women between 22 and 34 weeks of gestation who presented with threatened preterm labor.

Exclusion Criteria:

• Multiple pregnancies

• Women with Preterm Prelabour Rupture of Membrane

• Fetal death

• Women with bad obstetric history

• Women with history of cervical incompetence

• Contraindication to Nifedipine such as cardiovascular disease, hyperthyroidism, severe pre eclampsia or to Utrogestan

• Maternal or fetal indication for immediate delivery, such as fetal distress, bleeding placenta previa, abruption placenta

• Contraindication for tocolysis, for example severe pre eclampsia, intrauterine growth restriction, fetal anomaly, chorioamnionitis, significant antepartum haemorrhage

• Cervical dilatation of 3cm or more

• Patients with previous tocolytic treatment during this pregnancy

• Women who refuse to participate in this study